American Journal of Pharmacological Sciences
ISSN (Print): 2327-6711 ISSN (Online): 2327-672X Website: Editor-in-chief: Srinivas NAMMI
Open Access
Journal Browser
American Journal of Pharmacological Sciences. 2014, 2(6), 100-102
DOI: 10.12691/ajps-2-6-1
Open AccessArticle

Physiologically-Based IVIVC of Azithromycin

Nasir M. Idkaidek1, , Naji Najib2, Isam Salem2 and Jamal Jilani3

1College of Pharmacy, Petra University, Amman, Jordan

2International Pharmaceutical Research Center, Amman, Jordan

3College of Pharmacy, Jordan University of Science and Technology, Irbid, Jordan

Pub. Date: December 10, 2014

Cite this paper:
Nasir M. Idkaidek, Naji Najib, Isam Salem and Jamal Jilani. Physiologically-Based IVIVC of Azithromycin. American Journal of Pharmacological Sciences. 2014; 2(6):100-102. doi: 10.12691/ajps-2-6-1


Aim of the study is to establish physiologically-based in vitro in vivo correlation (IVIVC) of azithromycin, a biopharmaceutics classification system (BCS) class II drug (high permeability/ low solubility). In vitro dissolution was done using USP apparatus II in pH 6 phosphate buffer at 50 rpm. In vivo pharmacokinetic study was done on 28 healthy humans after IRB and Jordan FDA approvals. Plasma sampling was collected up to 72 hours. Non compartmental analysis was done using Kinetica program V 5. Physiologically based IVIVC was conducted using linear IVIVC module of SimCYP program V 13. Physiological parameter of effective intestinal permeability was optimized along with IVIVC calculations. IVIVC dissolution prediction matched in vivo profile with 1% and 7.7% prediction errors for AUC72 and Cmax, indicating proper physiologically based IVIVC. This is in agreement with IVIVC expectation for class II drugs according to (BCS) when in vitro dissolution rate is similar to in vivo dissolution rate. This is important for drug formulators to predict in vivo bioavailability from in vitro dissolution, which can save time and money.

azithromycin IVIVC SimCYP Intestinal Permeability

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit


[1]  Azithromycin data sheet:
[2]  Wildfeuer A, Laufen H, Leiold M et al, Comparison of the pharmacokinetics of three-day and five-day regimens of azithromycin in plasma and urine. J Antimicrob. Chemother. 1993; 31: 51-56.
[3]  Schentag J J & Batlow CH. Tissue-directed pharmacokinetics. Am. J. Med. 1999; 91 (suppl. 3A): 5S-11S.
[4]  Peters DH, Friedel HA, McTavish D. Azithromycin: A review of its antimicrobial activity, pharmacokinetic properties and clinical efficacy. Drugs. 1992; 44:750-99.
[5]  Lalak NJ, Morris DL. Azithromycin clinical pharmacokinetics. Clin Pharmacokinet. 1993; 25: 370-4.
[6]  Kelsey JJ, Moser LR, Jennings JC, Munger MA. Presence of azithromycin breast milk concentrations: a case report. Am J Obstet Gynecol. 1994; 170: 1375-6.
[7]  Nahata MC, Koranyi KI, Gadgil SD, Hilligoss DM, Fouda HG, Gardner MJ Pharmacokinetics of azithromycin in pediatric patients after oral administration of multiple doses of suspension. Antimicrob Agents Chemother. 1993; 37: 314-6.
[8]  J. B. Dressman, G. L. Amidon, C. Reppas, and V. P. Shah, Dissolution testing as a prognostic tool for oral drug absorption: immediate release dosage forms, Pharm. Res., 1998, 15 (1): 11-22.
[9]  Jamei M, Turner D, Yang J, Neuhoff S, Polak S, Rostami-Hodjegan A and Tucker G. Population-based mechanistic prediction of oral drug absorption. AAPS J. 2009 Jun; 11 (2): 225-37.
[10]  Chi-Yuan Wu and Leslie Z. Benet. Predicting Drug Disposition via Application of BCS: Transport/Absorption/Elimination Interplay and Development of a Biopharmaceutics Drug Disposition Classification System. Pharmaceutical Researh 2005 January; 22 (1): 11-23.